Overview

Neuroendocrine Risk for PTSD in Women

Status:
Recruiting
Trial end date:
2024-04-01
Target enrollment:
Participant gender:
Summary
This study will test for effects of estradiol (E2) on PTSD symptoms and functional magnetic resonance imaging (fMRI) indicators of stress vulnerability, in naturally-cycling women who are not using hormonal birth control. Enrollment will be targeted to create three groups within two cohorts (early follicular phase and luteal phase): 1. PTSD: Women who meet Diagnostic and Statistical Manual of Mental Disorders (DSM-5) criteria for PTSD 2. Trauma-Exposed (TC): Women matched for age and trauma exposure severity but without PTSD 3. Healthy Control (HC): Women matched for age, but without trauma history or psychiatric disorder (self-reported) Women will be recruited through Grady Trauma Project (GTP), a large longstanding study of civilian trauma and PTSD conducted at Grady Memorial Hospital in Atlanta, Georgia.
Phase:
Early Phase 1
Details
Lead Sponsor:
Emory University
Collaborator:
National Institute of Mental Health (NIMH)
Treatments:
Estradiol
Estradiol 17 beta-cypionate
Estradiol 3-benzoate
Polyestradiol phosphate